106 related articles for article (PubMed ID: 3098416)
21. 5-OH-dopa, product of and substrate for tyrosinase.
Agrup G; Rorsman H; Rosengren E
Acta Derm Venereol; 1982; 62(5):371-76. PubMed ID: 6183884
[TBL] [Abstract][Full Text] [Related]
22. An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid.
Fornstedt B; Bergh I; Rosengren E; Carlsson A
J Neurochem; 1990 Feb; 54(2):578-86. PubMed ID: 2105377
[TBL] [Abstract][Full Text] [Related]
23. [High-performance liquid chromatographic determination of urinary 5-S, 2-S-, 6-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa (author's transl)].
Morishima T; Saito M; Fujita M; Fukada E; Hanawa S
Nihon Hifuka Gakkai Zasshi; 1982 Jan; 92(1):53-6. PubMed ID: 6804671
[No Abstract] [Full Text] [Related]
24. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine.
Kågedal B; Källberg M; Arstrand K; Hansson C
J Chromatogr; 1989 Jul; 473(2):359-70. PubMed ID: 2504759
[TBL] [Abstract][Full Text] [Related]
25. Selective toxicity of 5-S-cysteinyldopa, a melanin precursor, to tumor cells in vitro and in vivo.
Fujita K; Ito S; Inoue S; Yamamoto Y; Takeuchi J; Shamoto M; Nagatsu T
Cancer Res; 1980 Jul; 40(7):2543-6. PubMed ID: 6771000
[TBL] [Abstract][Full Text] [Related]
26. 5-S-Cysteinyldopa in ganglion stellatum.
Fehling C; Hansson C; Poulsen J; Rorsman H; Rosengren E
J Neural Transm; 1981; 52(3):251-7. PubMed ID: 6796651
[TBL] [Abstract][Full Text] [Related]
27. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species.
Fornstedt B; Rosengren E; Carlsson A
Neuropharmacology; 1986 Apr; 25(4):451-4. PubMed ID: 3086766
[TBL] [Abstract][Full Text] [Related]
28. [Contents of cysteinyldopa isomers and DOPA in lesions of malignant melanoma (author's transl)].
Morishima T; Saito M; Fujita M; Fukada E; Nagashima N; Hanawa S
Nihon Hifuka Gakkai Zasshi; 1982 Feb; 92(2):157-9. PubMed ID: 6806514
[No Abstract] [Full Text] [Related]
29. Protein-bound dopa and 5-S-cysteinyldopa in non-melanogenic tissues.
Ito S; Jimbow K; Kato T; Kiyota M; Fujita K
Acta Derm Venereol; 1983; 63(6):463-7. PubMed ID: 6198833
[TBL] [Abstract][Full Text] [Related]
30. Formation of glutathionedopa in albino rats after DOPA injection.
Fehling C; Hansson C; Poulsen J; Rorsman H; Rosengren E
Acta Derm Venereol; 1981; 61(4):339-42. PubMed ID: 6173990
[No Abstract] [Full Text] [Related]
31. 5-S-cysteinyldopa and trichochromes in red feathers.
Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1978; 58(3):269-70. PubMed ID: 78644
[TBL] [Abstract][Full Text] [Related]
32. The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic.
Risser J; Pressley Z; Veledar E; Washington C; Chen SC
J Am Acad Dermatol; 2007 Sep; 57(3):428-34. PubMed ID: 17624623
[TBL] [Abstract][Full Text] [Related]
33. Solitary small active junctional nevi in juvenile patients.
Eng AM
Arch Dermatol; 1983 Jan; 119(1):35-8. PubMed ID: 6849562
[TBL] [Abstract][Full Text] [Related]
34. Determination of urinary 5-S-cysteinyldopa by high-performance liquid chromatography.
Kågedal B; Pettersson A
J Chromatogr; 1983 Feb; 272(2):287-97. PubMed ID: 6403561
[TBL] [Abstract][Full Text] [Related]
35. A new concept of melanocytic neoplasia pathogenesis based on the phenotype of common acquired nevi.
Batistatou A; Zioga A; Panelos J; Massi D; Agnantis NJ; Charalabopoulos K
Med Hypotheses; 2007; 69(6):1334-9. PubMed ID: 17459602
[TBL] [Abstract][Full Text] [Related]
36. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
[TBL] [Abstract][Full Text] [Related]
37. Melanocytic nevi with features of Spitz nevi and Clark's/dysplastic nevi ("Spark's" nevi).
Ko CJ; McNiff JM; Glusac EJ
J Cutan Pathol; 2009 Oct; 36(10):1063-8. PubMed ID: 19187111
[TBL] [Abstract][Full Text] [Related]
38. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
[TBL] [Abstract][Full Text] [Related]
39. Relative frequency of solitary melanocytic lesions of the oral mucosa.
Buchner A; Merrell PW; Carpenter WM
J Oral Pathol Med; 2004 Oct; 33(9):550-7. PubMed ID: 15357676
[TBL] [Abstract][Full Text] [Related]
40. Dysplastic melanocytic nevi and prognostically indeterminate nevomelanomatoid proliferations.
Kim JC; Murphy GF
Clin Lab Med; 2000 Dec; 20(4):691-712. PubMed ID: 11221510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
